The results of an EGFR-positive relapsed/refractory (R/R) NSCLC clinical trial (NCT01869166) showed that none of the patients experienced significant toxic side effects after anti-EGFR CAR-T cell therapy, two patients achieved partial remission, and five patients had stable disease for 2-8 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.